Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Interesting Big Picture view from Robert S ....
In "Why The Relaxation In Lockdowns Is Expected To Drive The Demand For COVID-19 Diagnostics Market
A recent report from Polaris Market Research said that the global COVID-19 diagnostics market was valued at USD 19.41 billion in 2020 and is expected to reach USD 23.67 billion by 2027 to grow at a CAGR of 2.9% during the forecast period. Active healthcare stocks in the markets this week include Novavax, Inc. (NASDAQ: NVAX), Global WholeHealth Partners Corp (OTCPK: GWHP), Sorrento Therapeutics, Inc. (NASDAQ: SRNE), Moderna, Inc. (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE).
https://www.prnewswire.com/news-releases/why-the-relaxation-in-lockdowns-is-expected-to-drive-the-demand-for-covid-19-diagnostics-market-301304896.html

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) recently announced that the Mexican Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), the health regulatory authority for Mexico, has listed COVI-STIX on its official government website list of rapid antigen tests approved for emergency use in Mexico. COVI-STIX is a rapid (approximately 15-minute) diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients ("Inmunoensayo de flujo lateral para la detección cualitativa de la proteína nucleocápside del SARS-CoV-2").

An independent study conducted by the government's epidemiological department, Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), confirmed the validity of the test in 465 nasopharyngeal samples from symptomatic (7 days or less) or uninfected people, which yielded the following results: Positive Predictive Value (PPV): 95.77%; Negative Predictive Value (NPV): 98.42%. Among all the products listed currently, COVI-STIX outperformed for both Sensitivity (91.89%) and Specificity (99.23%).

We're now listed with some of the largest Pharmaceutical Companies in the World. Know what you own my friends. BlackRock, Vanguard, and State Street invented over $250M in Sorrento stock. They didn't invest only to short the stock. They have a long term 3 year plan. If you have patience and willing to wait it out. Sorrento will be a $200B - $300B company before you know it. Please do your DD and invest what you can afford. In my best opinion Sorrento Therapeutics is by far the next Regeneron Pharmaceuticals X10.

For some of you that don't know on this board. My wife and I invested in Regeneron over 27 years ago. We became millionaires investing with REGN. Follow the money trial and you all will become millionaires someday. Don't be shaken or insulted or scared by paid short traders on this board. It's their job to disrupt and make you angry and leave. Don't let them win. Purchase your shares and forget you own the stock. That's what my wife and I did over 27 years ago. Thank you for listening."